Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma : A Phase II, Multicenter, Single-arm Trial (ESCOAT Trial)
Latest Information Update: 18 Feb 2025
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab
- Indications Carcinoma; Liver cancer; Oesophageal varices
- Focus Therapeutic Use
- Acronyms ESCOAT Trial
- 18 Feb 2025 New trial record